Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTOR: Phase II Temsirolimus as Second-Line Treatment for Metastatic RCC
2008-006798-33Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in metastatic renal cell carcinoma (mRCC), sponsored by Consorzio Oncotech. Primary endpoints: Progression-free survival rate at 6 months, Objective response rate (ORR) by RECIST and 1 more. Started Dec 2008; status: active.
02
Drugs
temsirolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-006798-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006798-33.